Agree(ADC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADC Agree

Not Yet Opened 01-14 16:00:00 EST

72.31

+0.90

+1.26%

盘后72.54

+0.23+0.32%

19:59 EST

High72.33	Low71.29	Vol1.61M
Open71.40	D1 Closing71.41	Amplitude1.46%
Mkt Cap8.31B	Tradable Cap7.84B	Total Shares114.93M
T/O115.91M	T/O Rate1.49%	Tradable Shares108.37M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ADC","market":"US","secType":"STK","nameCN":"Agree","latestPrice":72.31,"timestamp":1768424400000,"preClose":71.41,"halted":0,"volume":1609776,"hourTrading":{"tag":"盘后","latestPrice":72.5402,"preClose":72.31,"latestTime":"19:59 EST","volume":23156,"amount":1675799.7459,"timestamp":1768438753028},"delay":0,"floatShares":108366822,"shares":114934390,"eps":1.712089,"marketStatus":"Not Yet Opened","change":0.9,"latestTime":"01-14 16:00:00 EST","open":71.4,"high":72.33,"low":71.285,"amount":115912284.689376,"amplitude":0.014634,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.712089,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768467600000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":766296000000,"exchange":"NYSE","adjPreClose":71.41,"dividendRate":0.042235,"preHourTrading":{"tag":"盘前","latestPrice":71.72,"preClose":71.41,"latestTime":"09:28 EST","volume":21,"amount":1507.4499300000002,"timestamp":1768400910242},"postHourTrading":{"tag":"盘后","latestPrice":72.5402,"preClose":72.31,"latestTime":"19:59 EST","volume":23156,"amount":1675799.7459,"timestamp":1768438753028},"volumeRatio":0.9135622603939098,"impliedVol":0.231,"impliedVolPercentile":0.636},"requestUrl":"/m/hq/s/ADC/wiki","defaultTab":"wiki","newsList":[{"id":"2603647610","title":"Kaiser Permanente Affiliates Agree to Pay $556M to Resolve False Claims Act Allegations","url":"https://stock-news.laohu8.com/highlight/detail?id=2603647610","media":"Dow Jones","labels":["policyRegulatory"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/2603647610?lang=en_us&edition=fundamental","pubTime":"2026-01-15 06:00","pubTimestamp":1768428000,"startTime":"0","endTime":"0","summary":"Affiliates of Kaiser Permanente agreed to pay $556 million to resolve allegations that they violated the False Claims Act.In a 2021 complaint, the U.S. alleged the affiliates submitted invalid diagnosis codes for Medicare Advantage Plan enrollees to receive higher payments from the government, violating rules from the Centers for Medicare and Medicaid Services.Kaiser owns and operates insurance companies that offer private health plans that Medicare beneficiaries can opt to enroll in instead of traditional Medicare.Such insurers, known as Medicare Advantage Organizations, are paid a fixed monthly amount for each Medicare beneficiary enrolled in their plans. The payments are based on certain risk factors, and are generally higher for sicker beneficiaries expected to incur higher healthcare costs, the Department of Justice said.\"Medicare relies on the accuracy of the information submitted by those plans,\" U.S. Attorney Peter McNeilly for the District of Colorado said. \"This resolution se","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kaiser Permanente Affiliates Agree to Pay $556M to Resolve False Claims Act Allegations","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","ADC","BK4080"],"gpt_icon":0},{"id":"1114069729","title":"Strong Earnings and Acquisition of TOT Biopharm Bolster WUXI XDC's (02268) Position in ADC CDMO Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1114069729","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114069729?lang=en_us&edition=fundamental","pubTime":"2026-01-14 23:39","pubTimestamp":1768405156,"startTime":"0","endTime":"0","summary":"On January 14, 2026, WUXI XDC (02268) issued a positive profit alert for its 2025 fiscal year and simultaneously disclosed its launch of a voluntary conditional cash offer to acquire TOT Biopharm....","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268","LU2488822045.USD","BK4231","BK4080","BK4139","SG9999014674.SGD","BK1141","CDMO","ADC"],"gpt_icon":0},{"id":"2603916016","title":"Agree Realty (ADC) Receives a Hold from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2603916016","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603916016?lang=en_us&edition=fundamental","pubTime":"2026-01-14 17:37","pubTimestamp":1768383453,"startTime":"0","endTime":"0","summary":"Barclays analyst Richard Hightower maintained a Hold rating on Agree Realty today and set a price target of $78.00. According to TipRanks, Hightowe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/agree-realty-adc-receives-a-hold-from-barclays-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/agree-realty-adc-receives-a-hold-from-barclays-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4080","ADC","BK4231"],"gpt_icon":0},{"id":"2603930658","title":"Agree Realty to Pay Monthly Dividend of $0.262 per Share, Payable Feb. 13 to Holders of Record Jan. 30","url":"https://stock-news.laohu8.com/highlight/detail?id=2603930658","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603930658?lang=en_us&edition=fundamental","pubTime":"2026-01-14 05:23","pubTimestamp":1768339407,"startTime":"0","endTime":"0","summary":"Agree Realty to Pay Monthly Dividend of $0.262 per Share, Payable Feb. 13 to Holders of Record Jan. 30","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADC","BK4231","BK4080"],"gpt_icon":0},{"id":"2603037630","title":"Press Release: Agree Realty Declares Monthly Common and Preferred Dividends","url":"https://stock-news.laohu8.com/highlight/detail?id=2603037630","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603037630?lang=en_us&edition=fundamental","pubTime":"2026-01-14 05:05","pubTimestamp":1768338300,"startTime":"0","endTime":"0","summary":"Agree Realty Corporation   today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.262 per common share. The monthly dividend reflects an annualized dividend amount of $3.144 per common share, representing a 3.6% increase over the annualized dividend amount of $3.036 per common share from the first quarter of 2025. The dividend is payable February 13, 2026 to stockholders of record at the close of business on January 30, 2026.Additionally, the Company's Board of Directors has authorized, and the Company has declared, a monthly cash dividend on its 4.25% Series A Cumulative Redeemable Preferred Stock of $0.08854 per depositary share, which is equivalent to $1.0625 per annum. The dividend is payable February 2, 2026 to stockholders of record at the close of business on January 23, 2026.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","BK4231","ADC"],"gpt_icon":0},{"id":"2603571932","title":"Biocytogen Pharma Expands ADC Collaboration with Acepodia; Shares Rise 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603571932","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603571932?lang=en_us&edition=fundamental","pubTime":"2026-01-13 11:51","pubTimestamp":1768276311,"startTime":"0","endTime":"0","summary":"Biocytogen Pharmaceuticals (HKG:2315) said it has entered into an option and license agreement with Acepodia to expand its collaboration on dual-payload bispecific antibody-drug conjugate programs, ac","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","ADC","BK4080","02315","BK4231"],"gpt_icon":0},{"id":"1146080787","title":"Hong Kong Stock Movement | HENLIUS (02696) Surges Over 8% Again, Broad-Spectrum Anti-Tumor PD-L1 ADC HLX43 Phase II Data for End-Line Esophageal Squamous Cell Carcinoma First Released","url":"https://stock-news.laohu8.com/highlight/detail?id=1146080787","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146080787?lang=en_us&edition=fundamental","pubTime":"2026-01-13 10:16","pubTimestamp":1768270598,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) surged over 8% again, with an increase of 8.05% at the time of writing, reaching HK$69.8, and a turnover of HK$18.6408 million. On January 9th, at the 2026 American Society of...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000306685.HKD","PD","BK4080","BK4231","HK0000306701.USD","HK0000320223.HKD","LU1169590202.USD","02696","LU1169589451.USD","HK0000320264.USD","BK4023","HK0000165453.HKD","ADC"],"gpt_icon":0},{"id":"2603657567","title":"Top Insider Makes Bold Move With Major Agree Realty Stock Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2603657567","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603657567?lang=en_us&edition=fundamental","pubTime":"2026-01-13 10:01","pubTimestamp":1768269678,"startTime":"0","endTime":"0","summary":"New insider activity at Agree Realty ( ($ADC) ) has taken place on January 12, 2026. Executive Chairman of the Board Richard Agree has made a signi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-insider-makes-bold-move-with-major-agree-realty-stock-purchase-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-insider-makes-bold-move-with-major-agree-realty-stock-purchase-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADC","BK4080","BK4231"],"gpt_icon":0},{"id":"2603578711","title":"RPMGlobal Holdings Says Caterpillar, FIRB Agree to Extend Deadline for Approval for Proposed Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2603578711","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603578711?lang=en_us&edition=fundamental","pubTime":"2026-01-13 09:31","pubTimestamp":1768267889,"startTime":"0","endTime":"0","summary":"RPMGlobal Holdings  said that Caterpillar and the Foreign Investment Review Board  agreed to extend the statutory deadline for FIRB approval to Jan. 23 for the proposed acquisition of the firm by Revolution HoldCo, a direct wholly-owned unit of Caterpillar, via a scheme of arrangement, according to a Tuesday Australian bourse filing.Caterpillar informed the firm that FIRB requires additional time to complete its assessment, per the filing.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0048573561.USD","LU2237438978.USD","LU0868494617.USD","LU1917777945.USD","BK4516","LU2023250504.SGD","BK4231","BK4588","LU0868494708.USD","LU2357305700.SGD","ADC","LU2106854487.HKD","IE00BSNM7G36.USD","LU1988902786.USD","RUL.AU","BK4597","LU1720051108.HKD","BK4149","LU2264538146.SGD","BK7016","IE00BD6J9T35.USD","LU1974910355.USD","BK4520","BK4532","LU1548497426.USD","CAT","LU1064131342.USD","LU0742534661.SGD","BK4080","BK4585","LU0251131958.USD","LU1720051017.SGD","LU0251142724.SGD","LU0942090050.USD"],"gpt_icon":0},{"id":"2603554286","title":"Executive Chairman Richard Agree Acquires Common Shares of Agree Realty Corporation","url":"https://stock-news.laohu8.com/highlight/detail?id=2603554286","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603554286?lang=en_us&edition=fundamental","pubTime":"2026-01-13 00:27","pubTimestamp":1768235236,"startTime":"0","endTime":"0","summary":"Richard Agree, Executive Chairman of the Board, reported the acquisition of common shares of Agree Realty Corporation. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agree Realty Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 12, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDLbTmSbS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Executive Chairman Richard Agree Acquires Common Shares of Agree Realty Corporation","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","BK4231","BK4080"],"gpt_icon":0},{"id":"2602025514","title":"Agree Realty Corp : Bmo Cuts Target Price to $80 From $85","url":"https://stock-news.laohu8.com/highlight/detail?id=2602025514","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602025514?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:10","pubTimestamp":1768219821,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD1BE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ADC","BK4231","BK4080"],"gpt_icon":0},{"id":"2602653465","title":"Zymeworks Sets 2026 Strategy on Zanidatamab Momentum, ADC Pipeline and Cash-Fueled Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2602653465","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602653465?lang=en_us&edition=fundamental","pubTime":"2026-01-12 07:32","pubTimestamp":1768174361,"startTime":"0","endTime":"0","summary":"Zymeworks ( ($ZYME) ) has issued an update. Zymeworks has outlined its strategic priorities for 2026 following what it describes as a transformativ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/zymeworks-sets-2026-strategy-on-zanidatamab-momentum-adc-pipeline-and-cash-fueled-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/zymeworks-sets-2026-strategy-on-zanidatamab-momentum-adc-pipeline-and-cash-fueled-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADC","BK4080","BK4231"],"gpt_icon":0},{"id":"2602634505","title":"Zymeworks Outlines Strategic Priorities and Outlook for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602634505","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602634505?lang=en_us&edition=fundamental","pubTime":"2026-01-12 07:00","pubTimestamp":1768172400,"startTime":"0","endTime":"0","summary":"Positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in first-line HER2-positive (HER2+)gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone p","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/11/3216504/0/en/Zymeworks-Outlines-Strategic-Priorities-and-Outlook-for-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","LU0788108826.HKD","LU0368265764.SGD","LU0498741890.SGD","BK4097","LU0788109121.HKD","PFS","SG9999001143.SGD","LU0330918003.SGD","OS","LU0300736062.USD","BK4161","LU0345780281.USD","LU0345780950.USD","SG9999002521.SGD","BK4166","BK4080","BK4231","LU0300736492.USD","LU0345781412.USD","LU0724618789.USD","LU0055631609.USD","BK4211","LU0612318385.USD","ADC","LU0654597011.USD","LU0630314457.HKD","LU1023059493.AUD","PT","B","LU0612318971.USD","LU0345780521.USD","LU0075056555.USD","LU0496367417.USD","BK4195","LU0498741114.HKD","BK4017","LU1430597077.USD"],"gpt_icon":0},{"id":"2602563393","title":"Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2602563393","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602563393?lang=en_us&edition=fundamental","pubTime":"2026-01-12 06:00","pubTimestamp":1768168800,"startTime":"0","endTime":"0","summary":"Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporat","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/11/3216499/0/en/Day-One-Announces-Preliminary-2025-OJEMDA-Net-Product-Revenue-And-Provides-2026-Net-Product-Revenue-Guidance.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","ADC","BK4231","SOC","BK4213"],"gpt_icon":0},{"id":"2602300920","title":"Why Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) Is Up 18.9% After Breakthrough ADC Milestones And Global Tie-Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2602300920","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602300920?lang=en_us&edition=fundamental","pubTime":"2026-01-10 01:19","pubTimestamp":1767979187,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical recently reported that its TROP2-directed ADC sacituzumab tirumotecan, combined with pembrolizumab, received Breakthrough Therapy Designation in China for first-line PD-L1-positive NSCLC, while its ITGB6-targeted ADC SKB105 secured IND approval for advanced solid tumors and a new global collaboration with Crescent Biopharma was announced.\nThese developments, alongside multiple ongoing registrational and Phase 3 trials and structured distribution and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/why-sichuan-kelun-biotech-biopharmaceutical-sehk6990-is-up-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/why-sichuan-kelun-biotech-biopharmaceutical-sehk6990-is-up-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4080","BK4231","06990","BK1161","LU0196878994.USD","ADC"],"gpt_icon":0},{"id":"1130833898","title":"Beyond the Title: The Significance Behind the Recognition","url":"https://stock-news.laohu8.com/highlight/detail?id=1130833898","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130833898?lang=en_us&edition=fundamental","pubTime":"2026-01-09 06:52","pubTimestamp":1767912730,"startTime":"0","endTime":"0","summary":"The process for how Sichuan identifies headquarters enterprises involves legal entity enterprises that are registered in Sichuan, fulfill functions such as tax payment, statistical reporting, and...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1223083913.SGD","LU1223082519.USD","BK4017","BK4231","LU1223082196.USD","ADC","CDE","BK4080"],"gpt_icon":0},{"id":"2602316592","title":"ADC Therapeutics Announces Preliminary 2025 Financial Results and Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2602316592","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602316592?lang=en_us&edition=fundamental","pubTime":"2026-01-09 06:28","pubTimestamp":1767911336,"startTime":"0","endTime":"0","summary":"ADC Therapeutics ( ($ADCT) ) has provided an update. On January 8, 2026, ADC Therapeutics reported preliminary, unaudited 2025 financial figures in...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/adc-therapeutics-announces-preliminary-2025-financial-results-and-outlook?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/adc-therapeutics-announces-preliminary-2025-financial-results-and-outlook?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","BK4231","ADC","BK4539","LENZ","BK4080"],"gpt_icon":0},{"id":"2602318738","title":"ADC Therapeutics sees FY25 net product revenue $73M","url":"https://stock-news.laohu8.com/highlight/detail?id=2602318738","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602318738?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:17","pubTimestamp":1767907038,"startTime":"0","endTime":"0","summary":"FY25 revenue consensus $76.6M. “During 2025, we delivered meaningful progress across our ZYNLONTA clinical program and extended our expected cash r...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adc-therapeutics-sees-fy25-net-product-revenue-73m-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adc-therapeutics-sees-fy25-net-product-revenue-73m-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADC","LENZ"],"gpt_icon":0},{"id":"2602318291","title":"ADC Therapeutics sees Q4 net product revenue $22M","url":"https://stock-news.laohu8.com/highlight/detail?id=2602318291","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602318291?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:10","pubTimestamp":1767906645,"startTime":"0","endTime":"0","summary":"Q4 revenue consensus $18.29M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adc-therapeutics-sees-q4-net-product-revenue-22m-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adc-therapeutics-sees-q4-net-product-revenue-22m-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","ADC"],"gpt_icon":0},{"id":"2601236783","title":"ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004","url":"https://stock-news.laohu8.com/highlight/detail?id=2601236783","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601236783?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:30","pubTimestamp":1767879000,"startTime":"0","endTime":"0","summary":"- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of chemotherapy in HER2-positive metastatic breast cancer; interim a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/08/3215379/0/en/ALX-Oncology-Advances-Separate-Clinical-Trials-Evaluating-Investigational-CD47-Inhibitor-Evorpacept-and-Novel-EGFR-Targeted-Antibody-Drug-Conjugate-ALX2004.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","OS","BK4195","ORR","ALX","ADC","BK4097","BK4080","LU0456854461.SGD","CRC","BK4231","LU0266512127.USD","BK4211","BK4213"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.agreerealty.com","stockEarnings":[{"period":"1week","weight":0.0263},{"period":"1month","weight":0.0064},{"period":"3month","weight":-0.03},{"period":"6month","weight":0.0095},{"period":"1year","weight":0.0235},{"period":"ytd","weight":0.0039}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0141},{"period":"3month","weight":0.045},{"period":"6month","weight":0.1},{"period":"1year","weight":0.1858},{"period":"ytd","weight":0.0124}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Agree Realty Corporation (the Company), a Maryland corporation, is a fully integrated real estate investment trust (REIT) primarily focused on the ownership, acquisition, development and management of retail properties net leased to industry leading tenants. The Company was founded in 1971 by its current Executive Chairman, Richard Agree, and its common stock was listed on the New York Stock Exchange in 1994. As of March 31, 2024, the Company owned 2,161 properties, with a total gross leasable area (GLA) of approximately 44.9 million square feet.","yearOnYearQuotes":[{"month":1,"riseRate":0.59375,"avgChangeRate":-0.003544},{"month":2,"riseRate":0.451613,"avgChangeRate":-0.001428},{"month":3,"riseRate":0.580645,"avgChangeRate":0.015289},{"month":4,"riseRate":0.580645,"avgChangeRate":0.002795},{"month":5,"riseRate":0.5,"avgChangeRate":0.015633},{"month":6,"riseRate":0.65625,"avgChangeRate":0.010123},{"month":7,"riseRate":0.65625,"avgChangeRate":0.022845},{"month":8,"riseRate":0.46875,"avgChangeRate":0.002201},{"month":9,"riseRate":0.46875,"avgChangeRate":-0.006321},{"month":10,"riseRate":0.5625,"avgChangeRate":-0.000339},{"month":11,"riseRate":0.65625,"avgChangeRate":0.003584},{"month":12,"riseRate":0.46875,"avgChangeRate":0.00994}],"exchange":"NYSE","name":"Agree","nameEN":"Agree"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Agree(ADC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Agree(ADC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Agree,ADC,Agree股票,Agree股票老虎,Agree股票老虎国际,Agree行情,Agree股票行情,Agree股价,Agree股市,Agree股票价格,Agree股票交易,Agree股票购买,Agree股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Agree(ADC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Agree(ADC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction